JPMorgan Chase & Co. Begins Coverage on Septerna (NASDAQ:SEPN)

Equities research analysts at JPMorgan Chase & Co. began coverage on shares of Septerna (NASDAQ:SEPN) in a report issued on Tuesday, MarketBeat reports. The brokerage set an “overweight” rating and a $38.00 price target on the stock. JPMorgan Chase & Co.‘s price target suggests a potential upside of 68.89% from the company’s current price.

Other research analysts also recently issued reports about the stock. Wells Fargo & Company initiated coverage on shares of Septerna in a research report on Tuesday. They issued an “overweight” rating and a $43.00 price target on the stock. Cantor Fitzgerald initiated coverage on shares of Septerna in a research note on Tuesday. They issued an “overweight” rating and a $50.00 price objective on the stock. Finally, TD Cowen began coverage on shares of Septerna in a research report on Tuesday. They issued a “buy” rating for the company.

Septerna Stock Performance

Shares of SEPN opened at $22.50 on Tuesday. Septerna has a twelve month low of $18.62 and a twelve month high of $26.34.

Insiders Place Their Bets

In other news, major shareholder Rock Ventures V. L.P. Third acquired 370,500 shares of the stock in a transaction dated Monday, October 28th. The stock was bought at an average price of $18.00 per share, with a total value of $6,669,000.00. Following the completion of the purchase, the insider now directly owns 6,215,591 shares of the company’s stock, valued at $111,880,638. This represents a 6.34 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.